Onco immunology (ISSN: 2162-4011) is an eye-catching open access journal, published by Taylor &; Published by Francis Group, it is dedicated to providing high-quality research on basic and applied tumor immunology. This paper mainly introduces the foundation, migration and clinical field of tumor immunology. Although the publication time is not long, the starting point is very high, and 20 13 obtains the first impact factor, reaching 6.283.

OncoImmunology currently has three co-authors, namely, Dr. Lorenzo Galluzzi from Cornell Medical College in new york, USA, Dr. Guido Kroemer from Descartes University in Paris, France, and Dr. Laurence Zitvogel from Gustave Roussi Institute in France.

Influencing factors:

Tumor immunology has no influence factors for a long time. The first impact factor in 20 13 years is as high as 6.283, which was very prominent when it first appeared. In the following years, the influencing factors of OncoImmunology kept rising, reaching 7.7 19 at one time, and dropping to more than 5 points in 20 17, although it was only more than 5 points this year. The SCI impact factors of 20 15 to 20 19 are 7.644, 7.7 19, 5.503, 5.333 and 5.869, respectively.

Answer reference

It is suggested to find a formal professional translation company, such as International Scientific Editor, which is the first international company in China to provide language editing services and localization support. For decades, it has successfully provided language support for many scientific and technological workers in China to publish their papers. International science editors have 200 full-time editors and 500 part-time editors, and each article has to go through two rounds of polishing and proofreading to ensure that there is no problem with the language.